Amgen grabs FDA thumbs up for Soliris biosim, eyes 2025 launch
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its planned Stelara biosim rollout in 2025. But thanks to a new FDA approval, the company is nearing yet another biosimilar launch. The FDA …